Table 4.

Linear regression model predicting eGFR changes (in milliliters per minute) in patients with stage 1 or 2 CKD (n=39) over the study period

Predictors of eGFR ChangesUnivariate ModelMultivariable Model
β (95% CI)P Valueβ (95% CI)P Value
Age, per 10 yr−1.6 (−5.3 to 2.1)0.39−1.9 (−0.60 to 2.2)0.36
Sex, men versus women−2.2 (−8.6 to 4.1)0.49−2.4 (−9.6 to 4.6)0.48
Race, white versus nonwhite0.46 (−4.6 to 5.6)0.18−0.63 (−6.2 to 4.9)0.82
Diabetes versus nondiabetic−2.4 (−7.0 to 2.2)0.290.61 (−5.2 to 6.5)0.83
Cirrhosis versus noncirrhotic−4.8 (−9.3 to −0.39)0.03−6.3 (−11 to −1.4)0.02
Hypertension versus normotensive−4.4 (−13 to 4.1)0.30−6.4 (−16 to 4)0.23
Baseline eGFR, per 10-ml/min increase in eGFR−0.04 (−1.5 to 1.6)0.96−0.39 (−2.4 to 1.6)0.70
Achieving sustained virologic response−2.4 (−7.5 to 2.7)0.34−3.8 (−10 to 2.8)0.25
  • Model constructed to predict change in eGFR in milliliters per minute from baseline to 6-month follow-up period. Post-treatment follow-up eGFR is missing from n=2 patients with baseline eGFR ≥60 ml/min per 1.73 m2 and n=1 patient with baseline eGFR <60 ml/min per 1.73 m2. 95% CI, 95% confidence interval.